Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Foto på Patrik Edén

Patrik Edén

Universitetslektor

Foto på Patrik Edén

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.

Författare

  • Lena Nordström
  • Sandra Sernbo
  • Patrik Eden
  • Kirsten Grønbaek
  • Arne Kolstad
  • Riikka Räty
  • Marja-Liisa Karjalainen
  • Christian Geisler
  • Elisabeth Ralfkiaer
  • Christer Sundström
  • Anna Laurell
  • Jan Delabie
  • Mats Ehinger
  • Mats Jerkeman
  • Sara Ek
Visa allt

Summary, in English

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment-related morbidity, additional parameters need to be evaluated to enable risk-adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX11, TP53 (p53), MKI67 (Ki-67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker. Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions.

Avdelning/ar

  • Institutionen för immunteknologi
  • Institutionen för astronomi och teoretisk fysik - Har omorganiserats
  • Tumörmikromiljö
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Bröstcancer-genetik

Publiceringsår

2014

Språk

Engelska

Sidor

98-108

Publikation/Tidskrift/Serie

British Journal of Haematology

Volym

166

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Wiley-Blackwell

Ämne

  • Hematology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 0007-1048